| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25c4fc4e202922a16436d7d118f2043e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a631de8bfefafce15afbc0f53c411580
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_186669320337768f999bec90d76a5ca4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8c970e6479865823d534af891144b78 |
| publicationDate |
2014-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2449070-T3 |
| titleOfInvention |
Combination therapy with anti-CD20 antibodies type I and type II |
| abstract |
The use of an anti-CD20 type I antibody for the preparation of a medicament for the treatment of a cancer expressing CD20, characterized in that said anti-CD20 type I antibody is co-administered with an anti-CD20 type II antibody, characterized in that said anti-CD20 type I antibody is rituximab, said anti-CD20 type II antibody is a humanized B-Ly1 antibody, and at least 40% or more of the oligosaccharides of the Fc region of said anti-CD20 antibody type II are non-fucosylated, and said cancer expressing CD20 is a non-Hodgkin B-cell lymphoma (NHL), and wherein said humanized B-Ly1 antibody comprises a heavy chain variable region (VH) of Sec. No. 7 and a variable region of the light chain (VL) of Sec. No. 20 |
| priorityDate |
2007-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |